Specifically, in the Heart Outcomes Prevention Evaluation (HOPE) trial investigating the angiotensin-converting enzyme inhibitor, ramipril, patients who experienced regression/prevention of LVH had significantly lower risk of cardiovascular death, myocardial infarction, or stroke (p < 0.0001) [21]. This evidence concerns the gene ACE and stroke disorder.